Because of the low prevalence, not much is known about the natural history of patients with congenital disorders of glycosylation (CDG). Knowledge about the natural disease course is of major importance to inform patients and parents and to prepare intervention studies. The CDG Biobank contains biomaterial (DNA, plasma (EDTA and heparin) and urine) and specific data from the medical file of participating patients.
-
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
Sub-biobank MEMORY
15 September 2020The MEMORY biobank focuses on research into biomarkers for memory impairment and dementia and their validation in clinical cohorts.
read more
RYR1 sub-biobank
15 September 2020The RYR1 biobank is part of a study of the neuromuscular and multisystem features of patients with malignant hyperthermia or rhabdomyolysis related to RYR1 (ryanodine receptor type 1) variants.
read more
New colleague
15 September 2020My name is Robbert Croes and I started mid 2020 as a data-scientist at the Radboud Biobank.
read more
ProBCI sub-biobank
15 September 2020There is a pressing need for predictive biomarkers to personalize bladder cancer treatment.
read more
Financial regulation for sub-biobanks
15 September 2020Sub-biobanks are not required to pay up-front for the processing and storage of biomaterials. The effectiveness of this pre-financing agreement however is dependent on adherence to the demands regarding delivery and processing according to the Radboud Biobank standard operating procedures.
read more